Rosalind Advisors, Inc. has made a significant update by amending its Schedule 13D filing, which now shows it holds approximately 9.9% of the common stock of Delcath Systems, Inc. This move is noteworthy as it reflects the growing influence of investment firms within the surgical and medical instruments sector.
The filing, made on October 19, 2026, indicates that Rosalind Advisors, along with its affiliates, has a substantial ownership stake in Delcath Systems. This could potentially alter the dynamics among shareholders and influence future decisions at the company.
Background
Rosalind Advisors, Inc. is an investment advisory firm based in Toronto, Canada. The firm primarily focuses on public equity investments. Delcath Systems, Inc., the subject company of this filing, operates in the surgical and medical instruments and apparatus sector, as indicated by its Standard Industrial Classification (SIC) code of 3841.
Recent filings from Rosalind Advisors include a Schedule 13D/A on October 19, 2026, and a Form 4 on October 14, 2026. These filings highlight the firm’s ongoing engagement with its investments and its commitment to transparency.
What the Filing Says
The amended Schedule 13D filing reveals that Rosalind Advisors, Inc. holds a total of 6,692,491 shares of Delcath Systems, which translates to 9.9% of the company's common stock. The filing states, "The percentage set forth in Row 13... gives effect to such blockers," referring to limitations on the ability to convert preferred stock and exercise warrants due to ownership thresholds.
Impact
This significant stake by Rosalind Advisors may affect various stakeholders, including other shareholders, management at Delcath, and potential investors. The filing indicates that Steven Salamon, the President of Rosalind Advisors, and Gil Aharon, its Secretary, are key figures in this investment strategy.
What's Next
The filing does not specify what actions will follow this amendment. However, the substantial ownership stake may lead to increased scrutiny from other shareholders and could influence future corporate governance decisions at Delcath Systems.
For more details, see the filing under accession number 0001622627-26-000027.